Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study
Article 2023 en
Authors
SR
Serena Ruggieri
LP
Luca Prosperini
SA
Sarmad Al‐Araji
Abstract
1 min read
Early relapses and substantial MRI activity in the first year of treatment are associated with worse short-term outcomes in patients treated with some of the oral DMTs.
Claudio Gasperini, Luca Prosperini, Mar Tintoré, Maria Pia Sormani, Massimo Filippi, Jordi Río, Jacqueline Palace, Maria A. Rocca, Olga Ciccarelli, Frederik Barkhof, Jaume Sastre‐Garriga, Hugo Vrenken, Jette Lautrup Frederiksen, Tarek Yousry, Christian Enzinger, Àlex Rovira, Ludwig Kappos, Carlo Pozzilli, Xavier Montalbán, Nicola De Stefano
Maria Pia Sormani, Claudio Gasperini, Marzia Romeo, Jordi Río, Massimiliano Calabrese, Eleonora Cocco, Christian Enzingher, Franz Fazekas, Massimo Filippi, Antonio Gallo, Ludwig Kappos, Maria Giovanna Marrosu, Vittorio Martinelli, Luca Prosperini, Maria A. Rocca, Àlex Rovira, Till Sprenger, Maria Laura Stromillo, Gioacchino Tedeschi, Mar Tintoré, María Trojano, Xavier Montalbán, Carlo Pozzilli, Gıancarlo Comı,
Ermelinda De Meo, Massimo Filippi, Vincenzo Brescia Morra, Francesco Patti, Giorgia Teresa Maniscalco, Valentina Torri Clerici, Giuseppe Salemi, Marco Onofrj, Giacomo Lus, Marta Simone, María Trojano, Maria Pia Amato
Hans-Peter Hartung, Ludwig Kappos, Douglas S. Goodin, Paul O’Connor, Massimo Filippi, Barry G.W. Arnason, Giancarlo Comi, Stuart D. Cook, Douglas Jeffery, John Petkau, Richard White, Timon Bogumil, K. Beckmann, Brigitte Stemper, Gustavo Cruz, Rupert Sandbrink, Christoph Pohl
Discussion(0)
No comments yet. Be the first to comment.